Database : MEDLINE
Search on : Primary and Dysautonomias [Words]
References found : 225 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 23 go to page                         

  1 / 225 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28452849
[Au] Autor:Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
[Ad] Address:*Vanderbilt University School of Medicine †Department of Surgery ‡Division of Surgical Oncology, Vanderbilt University Medical Center, Nashville, TN.
[Ti] Title:Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
[So] Source:J Immunother;40(5):196-199, 2017 Jun.
[Is] ISSN:1537-4513
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Immune-related adverse events are common and well-documented in patients treated with ipilimumab, a cytotoxic T-lymphocyte antigen-4 monoclonal antibody approved for the treatment of metastatic and stage III melanoma. Neurological complications are rare, but widely variable and potentially devastating. Here, we discuss a case of a patient who was treated with a single dose of ipilimumab for resected stage III melanoma. She subsequently developed pandysautonomia that manifested as a tonically dilated pupil, gastrointestinal dysmotility, urinary retention, and profound orthostatic hypotension. Guillain-Barré syndrome was diagnosed on electromyography. She was treated with intravenous immunoglobulin, droxidopa, and supportive care, with prolonged but eventual recovery. Given the broadening use of ipilimumab in the treatment of advanced and metastatic melanoma, awareness and recognition of its profound immune-mediated adverse effects are essential.
[Mh] MeSH terms primary: Antineoplastic Agents/therapeutic use
Drug-Related Side Effects and Adverse Reactions/diagnosis
Guillain-Barre Syndrome/diagnosis
Immunotherapy/methods
Ipilimumab/therapeutic use
Melanoma/diagnosis
Primary Dysautonomias/diagnosis
Skin Neoplasms/diagnosis
[Mh] MeSH terms secundary: Adult
Antineoplastic Agents/adverse effects
CTLA-4 Antigen/immunology
Deglutition Disorders
Female
Guillain-Barre Syndrome/complications
Guillain-Barre Syndrome/therapy
Humans
Immunotherapy/adverse effects
Ipilimumab/adverse effects
Melanoma/complications
Melanoma/therapy
Primary Dysautonomias/etiology
Skin Neoplasms/complications
Skin Neoplasms/therapy
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (Ipilimumab)
[Em] Entry month:1801
[Cu] Class update date: 180116
[Lr] Last revision date:180116
[Js] Journal subset:IM
[Da] Date of entry for processing:170429
[St] Status:MEDLINE
[do] DOI:10.1097/CJI.0000000000000167

  2 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 28457055
[Au] Autor:Palmieri B; Laurino C; Vadalà M
[Ad] Address:Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy.
[Ti] Title:Short-Term Efficacy of CBD-Enriched Hemp Oil in Girls with Dysautonomic Syndrome after Human Papillomavirus Vaccination.
[So] Source:Isr Med Assoc J;19(2):79-84, 2017 Feb.
[Is] ISSN:1565-1088
[Cp] Country of publication:Israel
[La] Language:eng
[Ab] Abstract:BACKGROUND: Cannabidiol (CBD)-based treatments for several diseases, including Tourette's syndrome, multiple sclerosis, epilepsy, movement disorders and glaucoma, are proving to be beneficial and the scientific clinical background of the drug is continuously evolving. OBJECTIVES: To investigate the short-term effect of CBD-enriched hemp oil for relieving symptoms and improving the life quality (QOL) in young girls with adverse drug effects (ADRs) following human papillomavirus (HPV) vaccine. METHODS: In this anecdotal, retrospective, "compassionate-use", observational, open-label study, 12 females (age 12-24 years) with severe somatoform and dysautonomic syndrome following HPV vaccination were given sublingual CBD-rich hemp oil drops, 25 mg/kg per day supplemented by 2-5 mg/ml CBD once a week until a maximum dose of 150 mg/ml CBD per day was reached over a 3 month period. Patients' quality of life was evaluated using the medical outcome short-form health survey questionnaire (SF-36). RESULTS: Two patients dropped out due to iatrogenic adverse events and another two patients stopped the treatment early due to lack of any improvement. SF-36 showed significant benefits in the physical component score (P < 0.02), vitality (P < 0.03) and social role functioning (P < 0.02) after the treatment. The administration of hemp oil also significantly reduced body pain according to the SF-36 assessment. No significant differences from the start of treatment to several months post-treatment were detected in role limitations due to emotional reactions (P = 0.02). CONCLUSIONS: This study demonstrated the safety and tolerability of CBD-rich hemp oil and the primary efficacy endpoint. Randomized controlled trials are warranted to characterize the safety profile and efficacy of this compound.
[Mh] MeSH terms primary: Cannabidiol/administration & dosage
Papillomavirus Vaccines/adverse effects
Primary Dysautonomias
Quality of Life
Somatoform Disorders
[Mh] MeSH terms secundary: Administration, Sublingual
Adolescent
Autonomic Nervous System
Cannabidiol/adverse effects
Cannabinoid Receptor Agonists/administration & dosage
Cannabinoid Receptor Agonists/adverse effects
Cannabis
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Monitoring
Female
Humans
Italy
Papillomavirus Vaccines/administration & dosage
Plant Oils/administration & dosage
Primary Dysautonomias/diagnosis
Primary Dysautonomias/etiology
Primary Dysautonomias/psychology
Primary Dysautonomias/therapy
Retrospective Studies
Somatoform Disorders/diagnosis
Somatoform Disorders/etiology
Somatoform Disorders/psychology
Somatoform Disorders/therapy
Treatment Outcome
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Name of substance:0 (Cannabinoid Receptor Agonists); 0 (Papillomavirus Vaccines); 0 (Plant Oils); 19GBJ60SN5 (Cannabidiol)
[Em] Entry month:1711
[Cu] Class update date: 171130
[Lr] Last revision date:171130
[Js] Journal subset:IM
[Da] Date of entry for processing:170501
[St] Status:MEDLINE

  3 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28549077
[Au] Autor:Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
[Ad] Address:Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
[Ti] Title:Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
[So] Source:Brain;140(7):1959-1976, 2017 Jul 01.
[Is] ISSN:1460-2156
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Parkinson's disease varies widely in clinical manifestations, course of progression and biomarker profiles from person to person. Identification of distinct Parkinson's disease subtypes is of great priority to illuminate underlying pathophysiology, predict progression and develop more efficient personalized care approaches. There is currently no clear way to define and divide subtypes in Parkinson's disease. Using data from the Parkinson's Progression Markers Initiative, we aimed to identify distinct subgroups via cluster analysis of a comprehensive dataset at baseline (i.e. cross-sectionally) consisting of clinical characteristics, neuroimaging, biospecimen and genetic information, then to develop criteria to assign patients to a Parkinson's disease subtype. Four hundred and twenty-one individuals with de novo early Parkinson's disease were included from this prospective longitudinal multicentre cohort. Hierarchical cluster analysis was performed using data on demographic and genetic information, motor symptoms and signs, neuropsychological testing and other non-motor manifestations. The key classifiers in cluster analysis were a motor summary score and three non-motor features (cognitive impairment, rapid eye movement sleep behaviour disorder and dysautonomia). We then defined three distinct subtypes of Parkinson's disease patients: 223 patients were classified as 'mild motor-predominant' (defined as composite motor and all three non-motor scores below the 75th percentile), 52 as 'diffuse malignant' (composite motor score plus either ≥1/3 non-motor score >75th percentile, or all three non-motor scores >75th percentile) and 146 as 'intermediate'. On biomarkers, people with diffuse malignant Parkinson's disease had the lowest level of cerebrospinal fluid amyloid-ß (329.0 ± 96.7 pg/ml, P = 0.006) and amyloid-ß/total-tau ratio (8.2 ± 3.0, P = 0.032). Data from deformation-based magnetic resonance imaging morphometry demonstrated a Parkinson's disease-specific brain network had more atrophy in the diffuse malignant subtype, with the mild motor-predominant subtype having the least atrophy. Although disease duration at initial visit and follow-up time were similar between subtypes, patients with diffuse malignant Parkinson's disease progressed faster in overall prognosis (global composite outcome), with greater decline in cognition and in dopamine functional neuroimaging after an average of 2.7 years. In conclusion, we introduce new clinical criteria for subtyping Parkinson's disease based on a comprehensive list of clinical manifestations and biomarkers. This clinical subtyping can now be applied to individual patients for use in clinical practice using baseline clinical information. Even though all participants had a recent diagnosis of Parkinson's disease, patients with the diffuse malignant subtype already demonstrated a more profound dopaminergic deficit, increased atrophy in Parkinson's disease brain networks, a more Alzheimer's disease-like cerebrospinal fluid profile and faster progression of motor and cognitive deficits.
[Mh] MeSH terms primary: Amyloid beta-Peptides/cerebrospinal fluid
Parkinson Disease/classification
tau Proteins/cerebrospinal fluid
[Mh] MeSH terms secundary: Atrophy/pathology
Biomarkers/cerebrospinal fluid
Cognitive Dysfunction/complications
Disease Progression
Dopaminergic Neurons/pathology
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neuroimaging
Neuropsychological Tests
Parkinson Disease/cerebrospinal fluid
Parkinson Disease/complications
Parkinson Disease/pathology
Primary Dysautonomias/complications
Prospective Studies
REM Sleep Behavior Disorder/complications
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Name of substance:0 (Amyloid beta-Peptides); 0 (Biomarkers); 0 (tau Proteins)
[Em] Entry month:1708
[Cu] Class update date: 170830
[Lr] Last revision date:170830
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170527
[St] Status:MEDLINE
[do] DOI:10.1093/brain/awx118

  4 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28333983
[Au] Autor:McGorum BC; Symonds HW; Knottenbelt C; Cave TA; MacDonald SJ; Stratton J; Leon I; Turner JA; Pirie RS
[Ad] Address:Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Roslin, Midlothian, United Kingdom.
[Ti] Title:Alterations in amino acid status in cats with feline dysautonomia.
[So] Source:PLoS One;12(3):e0174346, 2017.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Feline dysautonomia (FD) is a multiple system neuropathy of unknown aetiology. An apparently identical disease occurs in horses (equine grass sickness, EGS), dogs, rabbits, hares, sheep, alpacas and llamas. Horses with acute EGS have a marked reduction in plasma concentrations of the sulphur amino acids (SAA) cyst(e)ine and methionine, which may reflect exposure to a neurotoxic xenobiotic. The aim of this study was to determine whether FD cats have alterations in amino acid profiles similar to those of EGS horses. Amino acids were quantified in plasma/serum from 14 FD cats, 5 healthy in-contact cats which shared housing and diet with the FD cats, and 6 healthy control cats which were housed separately from FD cats and which received a different diet. The adequacy of amino acids in the cats' diet was assessed by determining the amino acid content of tinned and dry pelleted foods collected immediately after occurrences of FD. Compared with controls, FD cats had increased concentrations of many essential amino acids, with the exception of methionine which was significantly reduced, and reductions in most non-essential amino acids. In-contact cats also had inadequate methionine status. Artefactual loss of cysteine during analysis precluded assessment of the cyst(e)ine status. Food analysis indicated that the low methionine status was unlikely to be attributable to dietary inadequacy of methionine or cystine. Multi-mycotoxin screening identified low concentrations of several mycotoxins in dry food from all 3 premises. While this indicates fungal contamination of the food, none of these mycotoxins appears to induce the specific clinico-pathologic features which characterise FD and equivalent multiple system neuropathies in other species. Instead, we hypothesise that ingestion of another, as yet unidentified, dietary neurotoxic mycotoxin or xenobiotic, may cause both the characteristic disease pathology and the plasma SAA depletion.
[Mh] MeSH terms primary: Amino Acids/blood
Cat Diseases/blood
Primary Dysautonomias/veterinary
[Mh] MeSH terms secundary: Animals
Cats
Female
Male
Primary Dysautonomias/blood
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Amino Acids)
[Em] Entry month:1708
[Cu] Class update date: 170825
[Lr] Last revision date:170825
[Js] Journal subset:IM
[Da] Date of entry for processing:170324
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0174346

  5 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28286166
[Au] Autor:Kumar B; Lenert P
[Ad] Address:Division of Immunology, University of Iowa, Iowa City. Electronic address: Bharat-Kumar@UIowa.edu.
[Ti] Title:Joint Hypermobility Syndrome: Recognizing a Commonly Overlooked Cause of Chronic Pain.
[So] Source:Am J Med;130(6):640-647, 2017 Jun.
[Is] ISSN:1555-7162
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Joint hypermobility syndrome, also known as benign hypermobility syndrome, is a connective tissue disease characterized by joint instability, chronic pain, and minor skin changes. It shares many clinical features of Ehlers-Danlos syndrome, Hypermobility Type; enough so that many authorities consider them as one disease process. Approximately 3% of the general population is believed to have joint hypermobility syndrome, but despite this high prevalence, due to lack of awareness, heterogeneity of clinical presentation, and reliance on physical examination for diagnosis, it is largely overlooked by primary care physicians as well as by specialists. This leads to delayed or missed opportunities for diagnosis, and inappropriate interventions that frustrate both providers and patients. We review the literature regarding the pathophysiology, diagnosis, treatment options, and prognosis of joint hypermobility syndrome, and advocate for primary care physicians to consider it in the differential diagnosis of patients with chronic pain.
[Mh] MeSH terms primary: Chronic Pain/etiology
Ehlers-Danlos Syndrome/diagnosis
[Mh] MeSH terms secundary: Abdominal Pain/etiology
Ehlers-Danlos Syndrome/epidemiology
Ehlers-Danlos Syndrome/physiopathology
Ehlers-Danlos Syndrome/therapy
Fatigue/etiology
Headache/etiology
Humans
Mitral Valve Prolapse/etiology
Musculoskeletal Pain/etiology
Pelvic Pain/etiology
Prevalence
Primary Dysautonomias/etiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1708
[Cu] Class update date: 170822
[Lr] Last revision date:170822
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170314
[St] Status:MEDLINE

  6 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28228131
[Au] Autor:Fang H; Wu Y; Yang H; Yoon M; Jiménez-Barrón LT; Mittelman D; Robison R; Wang K; Lyon GJ
[Ad] Address:Stanley Institute for Cognitive Genomics, One Bungtown Road, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
[Ti] Title:Whole genome sequencing of one complex pedigree illustrates challenges with genomic medicine.
[So] Source:BMC Med Genomics;10(1):10, 2017 Feb 23.
[Is] ISSN:1755-8794
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Human Phenotype Ontology (HPO) has risen as a useful tool for precision medicine by providing a standardized vocabulary of phenotypic abnormalities to describe presentations of human pathologies; however, there have been relatively few reports combining whole genome sequencing (WGS) and HPO, especially in the context of structural variants. METHODS: We illustrate an integrative analysis of WGS and HPO using an extended pedigree, which involves Prader-Willi Syndrome (PWS), hereditary hemochromatosis (HH), and dysautonomia-like symptoms. A comprehensive WGS pipeline was used to ensure reliable detection of genomic variants. Beyond variant filtering, we pursued phenotypic prioritization of candidate genes using Phenolyzer. RESULTS: Regarding PWS, WGS confirmed a 5.5 Mb de novo deletion of the parental allele at 15q11.2 to 15q13.1. Phenolyzer successfully returned the diagnosis of PWS, and pinpointed clinically relevant genes in the deletion. Further, Phenolyzer revealed how each of the genes is linked with the phenotypes represented by HPO terms. For HH, WGS identified a known disease variant (p.C282Y) in HFE of an affected female. Analysis of HPO terms alone fails to provide a correct diagnosis, but Phenolyzer successfully revealed the phenotype-genotype relationship using a disease-centric approach. Finally, Phenolyzer also revealed the complexity behind dysautonomia-like symptoms, and seven variants that might be associated with the phenotypes were identified by manual filtering based on a dominant inheritance model. CONCLUSIONS: The integration of WGS and HPO can inform comprehensive molecular diagnosis for patients, eliminate false positives and reveal novel insights into undiagnosed diseases. Due to extreme heterogeneity and insufficient knowledge of human diseases, it is also important that phenotypic and genomic data are standardized and shared simultaneously.
[Mh] MeSH terms primary: Genomics
Pedigree
Precision Medicine/methods
Sequence Analysis
[Mh] MeSH terms secundary: DNA Copy Number Variations
False Positive Reactions
Female
Genome, Human/genetics
Humans
Male
Molecular Sequence Annotation
Phenotype
Primary Dysautonomias/genetics
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171027
[Lr] Last revision date:171027
[Js] Journal subset:IM
[Da] Date of entry for processing:170224
[St] Status:MEDLINE
[do] DOI:10.1186/s12920-017-0246-5

  7 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28126506
[Au] Autor:Tranchant C
[Ad] Address:Hôpital de Hautepierre, service de neurologie, unité des pathologies du mouvement, 1, avenue Molière, 67000 Strasbourg, France. Electronic address: christine.tranchant@chru-strasbourg.fr.
[Ti] Title:Autres syndromes parkinsoniens. [Other causes of parkinsonism].
[So] Source:Presse Med;46(2 Pt 1):210-217, 2017 Mar.
[Is] ISSN:2213-0276
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:Numerous causes may induce parkinsonism, and in case of Parkinsonism, l-dopa resistance, associated neurological signs, early falls, early dysautonomia or early cognitive disorders are the main red flags which should lead to exclude Parkinson's disease. Drug-induced parkinsonism and in young people, Wilson disease, should always be searched. Lower limbs parkinsonism is often due to vascular lesions. Multiple systemic atrophy, supranuclear palsy, Lewy body disease and the rarer corticobasal degeneration, each have specific clinical signs. Genetic causes are rarer.
[Mh] MeSH terms primary: Parkinson Disease, Secondary/etiology
[Mh] MeSH terms secundary: Accidental Falls
Basal Ganglia Diseases/complications
Basal Ganglia Diseases/diagnosis
Diagnosis, Differential
Hepatolenticular Degeneration/complications
Humans
Iatrogenic Disease
Lewy Body Disease/diagnosis
Neurodegenerative Diseases/complications
Neurodegenerative Diseases/diagnosis
Neurodegenerative Diseases/genetics
Parkinson Disease/diagnosis
Parkinson Disease, Secondary/diagnosis
Primary Dysautonomias/complications
Primary Dysautonomias/diagnosis
Symptom Assessment
Vascular Diseases/complications
Vascular Diseases/diagnosis
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1704
[Cu] Class update date: 170406
[Lr] Last revision date:170406
[Js] Journal subset:IM
[Da] Date of entry for processing:170128
[St] Status:MEDLINE

  8 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28120078
[Au] Autor:Martín-Gallego A; González-García L; Carrasco-Brenes A; Segura-Fernández-Nogueras M; Delgado-Babiano A; Ros-Sanjuán A; Romero-Moreno L; Domínguez-Páez M; Dawid-Milner MS; Arráez-Sánchez MA
[Ad] Address:Department of Neurosurgery, Regional University Hospital of Málaga, Avenida Carlos Haya s/n, 29010, Málaga, Spain. alvaro1710@hotmail.com.
[Ti] Title:Brainstem and Autonomic Nervous System Dysfunction: A Neurosurgical Point of View.
[So] Source:Acta Neurochir Suppl;124:221-229, 2017.
[Is] ISSN:0065-1419
[Cp] Country of publication:Austria
[La] Language:eng
[Ab] Abstract:Central autonomic control nuclei and pathways are mainly integrated within the brainstem, especially in the medulla oblongata. Lesions within these structures can lead to central dysautonomia.Central autonomic control structures can be damaged by tumors, during surgery, or by other neurosurgical pathologies. These may elicit clinical or subclinical autonomic complications that can constitute a serious clinical problem.The authors present a broad review of the central autonomic nervous system, its possible dysfunctions, and the relation between neurosurgery and this "not-well-known system". Preliminary results of an autonomic study of brainstem lesions that is currently being carried out by the authors are also shown.
[Mh] MeSH terms primary: Brain Stem Neoplasms/surgery
Brain Stem/surgery
Postoperative Complications/physiopathology
Primary Dysautonomias/physiopathology
[Mh] MeSH terms secundary: Brain Stem/physiopathology
Brain Stem Neoplasms/complications
Humans
Primary Dysautonomias/etiology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1711
[Cu] Class update date: 171102
[Lr] Last revision date:171102
[Js] Journal subset:IM
[Da] Date of entry for processing:170126
[St] Status:MEDLINE
[do] DOI:10.1007/978-3-319-39546-3_34

  9 / 225 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28112424
[Au] Autor:Armstrong KR; De Souza AM; Sneddon PL; Potts JE; Claydon VE; Sanatani S
[Ad] Address:Children's Heart Centre, BC Children's Hospital, Vancouver, BC, Canada.
[Ti] Title:Exercise and the multidisciplinary holistic approach to adolescent dysautonomia.
[So] Source:Acta Paediatr;106(4):612-618, 2017 Apr.
[Is] ISSN:1651-2227
[Cp] Country of publication:Norway
[La] Language:eng
[Ab] Abstract:AIM: To determine whether an eight-week strength training programme as part of a multidisciplinary approach would minimise symptoms and improve quality of life in patients with dysautonomia. METHODS: Adolescents referred to a tertiary-level cardiology service from May 2014-December 2015 with symptoms of dysautonomia were eligible. Participants completed an exercise test and a quality of life (QoL) questionnaire (PedsQL) prior to the intervention. Participants were asked to complete exercises five times per week. After eight weeks, participants returned for follow-up testing. Parents completed a proxy report of their child's QoL at both time points. RESULTS: A total of 17 participants completed the study protocol with an adherence rate of up to 50%. Post-intervention, QoL scores improved across all levels in the participants [total 65.2 (50.4-74.7) vs 48.9 (37.5-63.0); p = 0.006; psychosocial 65.8 (56.1-74.6) vs 50.0 (41.7-65.8); p = 0.010; physical 62.5 (37.5-76.6) vs 43.8 (25-68.5); p = 0.007] and their parent proxy reports [total 63.5 (48.7-81.3) vs 50.0 (39.3-63.0); p = 0.004; psychosocial 62.1 (52.1-81.3) vs 50.0 (39.6-59.2); p = 0.001; physical 62.5 (51.6-80.0) vs 50.0 (27.5-70.3); p = 0.003]. Treadmill time also improved (9.1 vs 8.0 minutes; p = 0.005). CONCLUSION: Following an eight-week strength training programme, dysautonomia patients report a significant improvement in both their quality of life and endurance time.
[Mh] MeSH terms primary: Primary Dysautonomias/therapy
Resistance Training
[Mh] MeSH terms secundary: Adolescent
Female
Humans
Male
Prospective Studies
Quality of Life
Treatment Outcome
[Pt] Publication type:CLINICAL TRIAL; JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171004
[Lr] Last revision date:171004
[Js] Journal subset:IM
[Da] Date of entry for processing:170124
[St] Status:MEDLINE
[do] DOI:10.1111/apa.13750

  10 / 225 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 28073230
[Au] Autor:Garstad LJ; Mygland Å; Ljøstad U
[Ad] Address:Nevrologisk avdeling Sørlandet sykehus, Kristiansand.
[Ti] Title:En kvinne i 40-årene med anisokori og ensidig ansiktsrødme. [A woman in her 40s with anisocoria and unilateral facial flushing].
[So] Source:Tidsskr Nor Laegeforen;137(1):40-42, 2017 01.
[Is] ISSN:0807-7096
[Cp] Country of publication:Norway
[La] Language:nor
[Mh] MeSH terms primary: Anisocoria/etiology
Flushing/etiology
Primary Dysautonomias
[Mh] MeSH terms secundary: Adult
Face/pathology
Female
Humans
Middle Aged
Mydriasis/etiology
Primary Dysautonomias/complications
Primary Dysautonomias/diagnosis
Tonic Pupil/etiology
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1704
[Cu] Class update date: 170817
[Lr] Last revision date:170817
[Js] Journal subset:IM
[Da] Date of entry for processing:170112
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.16.0191


page 1 of 23 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information